-
平臺(tái)編號(hào)：bio-47744
-
國(guó)際編號(hào)：ATCC 50181
-
拉丁屬名： Plasmodium berghei
-
規(guī)格：frozen
-
用途：ATCC原裝進(jìn)口
-
服務(wù)費(fèi)用：
加載中…… - 訂購(gòu)
-
注意事項(xiàng)：僅用于科學(xué)研究或者工業(yè)應(yīng)用等非醫(yī)療目的不可用于人類或動(dòng)物的臨床診斷或治療，非藥用，非食用（產(chǎn)品信息以出庫(kù)為準(zhǔn)）
Plasmodium berghei
ATCC? Number:50181?
Organism: Plasmodium berghei Vincke and Lips
Designations: NK65D
Isolation: derived from M. Yoeli strain NK65 by mosquito passage, Univ. Illinois, Urbana, pre-1969
Depositors: NE Alger
Biosafety Level:1
Shipped: frozen
Growth Conditions: Duration: in vivo, mouse Protocol: ATCCNO: 50173 SPEC: This strain is distributed as a frozen stabilate. See general instructions for thawing and storage of frozen material before proceeding. Upon arrival remove the frozen ampoule from the dry ice and transfer directly to a 35C water bath. When completely thawed, aseptically remove the material with a syringe and inject the entire thawed contents of the ampule intraperitoneally into a 6- to 9-week-old mouse. The strain should be monitored, especially after infecting with thawed material. To infect additional mice, draw a drop of tail blood into a 1.0 ml syringe containing 0.5 ml of sterile buffered anticoagulant, mix, and inoculate 0.1-0.2 ml of the suspension intraperitoneally/rat.
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Malaria vaccine antigen [4702] [4705] Isolation of a vaccine fraction [5060] Variation in virulence [4769] Malaria resistance [5051]
Classification: KINGDOM: Protozoa
References: 4702: Boyer JM, et al. Lipid composition and activity of a lytic factor isolated from Plasmodium berghei. Infect. Immun. 25: 805-809, 1979. PubMed: 387594 4705: D'Antonio LE, et al. Malaria vaccine antigen(s): detergent solubilization, partial isolation, and recovery of immunoprotective activity. Infect. Immun. 43: 442-444, 1984. PubMed: 6360908 4769: Alger NE, et al. Plasmodium berghei NK65 in the inbred A-J mouse: variations in virulence of P. berghei demes. J. Protozool. 18: 598-601, 1971. PubMed: 5133123 4843: Alger NE, Keshavarz-Valian H. Plasmodium berghei: the effects of suppressor factor on vaccination. Int. J. Parasitol. 14: 301-307, 1984. PubMed: 6381347 4893: D'Antonio LE, et al. Model system for study of artificially induced resistance to malaria. Nature 223: 507-509, 1969. PubMed: 5796953 5051: D'Antonio LE, et al. Malaria resistance: artificial induction with a partially purified plasmodial fraction. Science 168: 1117-1118, 1970. PubMed: 5441687 5060: D'Antonio LE. Plasmodium: a resume of the isolation of the vaccine fraction by the French pressure cell technique. Exp. Parasitol. 31: 75-81, 1972. PubMed: 5010607
ATCC50181
Organism: Plasmodium berghei Vincke and Lips
Designations: NK65D
Isolation: derived from M. Yoeli strain NK65 by mosquito passage, Univ. Illinois, Urbana, pre-1969
Depositors: NE Alger
Biosafety Level:1
Shipped: frozen
Growth Conditions: Duration: in vivo, mouse Protocol: ATCCNO: 50173 SPEC: This strain is distributed as a frozen stabilate. See general instructions for thawing and storage of frozen material before proceeding. Upon arrival remove the frozen ampoule from the dry ice and transfer directly to a 35C water bath. When completely thawed, aseptically remove the material with a syringe and inject the entire thawed contents of the ampule intraperitoneally into a 6- to 9-week-old mouse. The strain should be monitored, especially after infecting with thawed material. To infect additional mice, draw a drop of tail blood into a 1.0 ml syringe containing 0.5 ml of sterile buffered anticoagulant, mix, and inoculate 0.1-0.2 ml of the suspension intraperitoneally/rat.
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Comments: Malaria vaccine antigen [4702] [4705] Isolation of a vaccine fraction [5060] Variation in virulence [4769] Malaria resistance [5051]
Classification: KINGDOM: Protozoa
References: 4702: Boyer JM, et al. Lipid composition and activity of a lytic factor isolated from Plasmodium berghei. Infect. Immun. 25: 805-809, 1979. PubMed: 387594 4705: D'Antonio LE, et al. Malaria vaccine antigen(s): detergent solubilization, partial isolation, and recovery of immunoprotective activity. Infect. Immun. 43: 442-444, 1984. PubMed: 6360908 4769: Alger NE, et al. Plasmodium berghei NK65 in the inbred A-J mouse: variations in virulence of P. berghei demes. J. Protozool. 18: 598-601, 1971. PubMed: 5133123 4843: Alger NE, Keshavarz-Valian H. Plasmodium berghei: the effects of suppressor factor on vaccination. Int. J. Parasitol. 14: 301-307, 1984. PubMed: 6381347 4893: D'Antonio LE, et al. Model system for study of artificially induced resistance to malaria. Nature 223: 507-509, 1969. PubMed: 5796953 5051: D'Antonio LE, et al. Malaria resistance: artificial induction with a partially purified plasmodial fraction. Science 168: 1117-1118, 1970. PubMed: 5441687 5060: D'Antonio LE. Plasmodium: a resume of the isolation of the vaccine fraction by the French pressure cell technique. Exp. Parasitol. 31: 75-81, 1972. PubMed: 5010607
ATCC50181
